Relmada Therapeutics

Relmada Therapeutics is a clinical-stage biotechnology company focused on developing treatments for central nervous system (CNS) diseases. Its lead product candidate, REL-1017, an NMDA receptor antagonist, is in late-stage development as an adjunctive treatment for major depressive disorder.

Sergio Traversa Ph.D

CEO and Board Member

Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.